Rhythm Pharmaceuticals (RYTM) focuses on treating rare forms of obesity caused by genetic disorders or damage to brain regions controlling hunger, a niche market currently untouched by giants like Eli Lilly and Novo Nordisk. The company's approved product, Imcivree, received a new indication approval in March this year for acquired hypothalamic obesity, quadrupling its potential market size.